RT Journal Article
SR Electronic
T1 Association between aspirin dose and outcomes in patients with acute Kawasaki disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.13.23285893
DO 10.1101/2023.02.13.23285893
A1 Suzuki, Takanori
A1 Michihata, Nobuaki
A1 Hashimoto, Yohei
A1 Yoshikawa, Tetsushi
A1 Saito, Kazuyoshi
A1 Matsui, Hiroki
A1 Fushimi, Kiyohide
A1 Yasunaga, Hideo
YR 2023
UL http://medrxiv.org/content/early/2023/02/21/2023.02.13.23285893.abstract
AB Background The most effective dosage of aspirin to prevent coronary artery abnormalities in patients with acute Kawasaki disease remains unknown. Using a Japanese national inpatient database, this study aimed to identify the appropriate dose of aspirin to be prescribed to patients with acute Kawasaki disease.Method We used the Diagnostic Procedure Combination database to identify patients with Kawasaki disease treated with intravenous immunoglobulin between 2010 and 2021.The outcomes included the occurrence of coronary artery abnormalities and intravenous immunoglobulin resistance, length of stay, and medical costs. Restricted cubic spline functions were performed to examine the association between aspirin dose and the outcomes.Results Data of 82109 patients were extracted from the database. Non-linear associations were observed between aspirin dose and the outcomes. In comparison with an aspirin dose of 30 mg/kg/day, the odds ratio (95% confidence interval) for coronary artery abnormalities was 1.40 (1.13–1.75) at 5 mg/kg/day. An aspirin dose of ≥30 mg/kg/day did not significantly change the odds ratio for coronary artery abnormalities. Compared with a dose of 30 mg/kg/day, the odds ratio (95% confidence interval) for intravenous immunoglobulin resistance was 0.87 (0.76–1.00) at 5 mg/kg/day and 0.59 (0.36–0.98) at 80 mg/kg/day. An increase in aspirin dose was associated with a shorter length of stay and lower medical costs.Conclusions Low-dose aspirin may increase the risk of coronary artery abnormalities in patients with acute Kawasaki disease; however, increasing aspirin doses beyond the standard doses may not be associated with a reduction in coronary artery abnormalities. High-dose aspirin showed the potential to reduce hospital stay and medical costs without increasing complications.Article Summary The study showed by restricted cubic spline that the dose of aspirin was no significant association between aspirin escalation and CAAs in patients with acute KD.What’s Known on This Subject Aspirin is standard treatments used with IVIG of acute Kawasaki Disease (KD), Few studies have shown the most effective dosage of aspirin to to prevent CAAs.What This Study Adds The dose of aspirin was no significant association between aspirin escalation and CAAs in patients with acute KD.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialhttps://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000056529Funding StatementThis work was supported by grants from the Ministry of Health, Labour and Welfare, Japan (21AA2007 and 22AA2003) and the Ministry of Education, Culture, Sports, Science and Technology, Japan (20H03907).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the Institutional Review Board of The University of Tokyo (approval number: 3501-(5) (May 19th, 2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe datasets analyzed during the current study are not publicly available due to contracts with the hospitals providing data to the database.ADLactivities of daily livingCAAcoronary artery abnormalitiesCIconfidence intervalICD-10International Classification of Diseases, Tenth RevisionIQRinterquartile rangeIVIGintravenous immunoglobulinKDKawasaki DiseaseSDstandard deviationUSDUnited States Dollar